- Home
- LYEL vs GBLI Comparison
LYEL vs GBLI Comparison
Compare LYEL & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LYEL | GBLI |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 395.4M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LYEL | GBLI |
|---|---|---|
| Price | $23.86 | $28.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $30.60 | N/A |
| AVG Volume (30 Days) | ★ 76.6K | 2.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.94% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.75 |
| Revenue | $36,000.00 | ★ $450,098,000.00 |
| Revenue This Year | N/A | $14.23 |
| Revenue Next Year | $16,285.34 | $9.68 |
| P/E Ratio | ★ N/A | $16.19 |
| Revenue Growth | N/A | ★ 2.02 |
| 52 Week Low | $0.39 | $25.88 |
| 52 Week High | $45.00 | $34.00 |
Technical Indicators
Market Signals| Indicator | LYEL | GBLI |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 55.25 |
| Support Level | $21.27 | $27.55 |
| Resistance Level | $27.30 | $28.81 |
| Average True Range (ATR) | 1.70 | 0.36 |
| MACD | 0.50 | 0.10 |
| Stochastic Oscillator | 80.58 | 100.00 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.